Short Seller Culper Attacks Tarsus Pharmaceuticals Over XDEMVY Market Size
Culper Research argues Tarsus is significantly overvalued, disputing the addressable market for its Demodex blepharitis drug XDEMVY.
Culper Research argues Tarsus is significantly overvalued, disputing the addressable market for its Demodex blepharitis drug XDEMVY.
Mizuho initiates coverage on Tarsus Pharmaceuticals with an Outperform rating and a $100 price target, citing strong prospects for Xdemvy and projected peak sales above $2B.